Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 248

1.

Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture.

Ferrari S, Reginster JY, Brandi ML, Kanis JA, Devogelaer JP, Kaufman JM, Féron JM, Kurth A, Rizzoli R.

Arch Osteoporos. 2016 Dec;11(1):37. Review.

PMID:
27800591
2.

A Comprehensive Fracture Prevention Strategy in Older Adults: The European Union Geriatric Medicine Society (EUGMS) Statement.

Blain H, Masud T, Dargent-Molina P, Martin FC, Rosendahl E, van der Velde N, Bousquet J, Benetos A, Cooper C, Kanis JA, Reginster JY, Rizzoli R, Cortet B, Barbagallo M, Dreinhöfer KE, Vellas B, Maggi S, Strandberg T; EUGMS Falls and Fracture Interest Group.; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), Osteoporosis Research and Information Group (GRIO), and International osteoporosis Foundation (IOF)..

J Nutr Health Aging. 2016;20(6):647-52. doi: 10.1007/s12603-016-0741-y.

3.

The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club.

Cavalier E, Bergmann P, Bruyère O, Delanaye P, Durnez A, Devogelaer JP, Ferrari SL, Gielen E, Goemaere S, Kaufman JM, Toukap AN, Reginster JY, Rousseau AF, Rozenberg S, Scheen AJ, Body JJ.

Osteoporos Int. 2016 Jul;27(7):2181-95. doi: 10.1007/s00198-016-3561-3.

PMID:
27026330
4.

High Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study.

Edwards MH, Parsons C, Bruyère O, Petit Dop F, Chapurlat R, Roemer FW, Guermazi A, Zaim S, Genant H, Reginster JY, Dennison EM, Cooper C; SEKOIA Study Group..

J Rheumatol. 2016 Mar;43(3):657-65. doi: 10.3899/jrheum.150053.

PMID:
26773120
5.

Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).

Cooper C, Bardin T, Brandi ML, Cacoub P, Caminis J, Civitelli R, Cutolo M, Dere W, Devogelaer JP, Diez-Perez A, Einhorn TA, Emonts P, Ethgen O, Kanis JA, Kaufman JM, Kvien TK, Lems WF, McCloskey E, Miossec P, Reiter S, Ringe J, Rizzoli R, Saag K, Reginster JY.

Aging Clin Exp Res. 2016 Feb;28(1):1-16. doi: 10.1007/s40520-015-0522-1. Review.

PMID:
26746234
6.

Effects of Dairy Products Consumption on Health: Benefits and Beliefs--A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.

Rozenberg S, Body JJ, Bruyère O, Bergmann P, Brandi ML, Cooper C, Devogelaer JP, Gielen E, Goemaere S, Kaufman JM, Rizzoli R, Reginster JY.

Calcif Tissue Int. 2016 Jan;98(1):1-17. doi: 10.1007/s00223-015-0062-x. Review.

7.

Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement.

Reginster JY, Reiter-Niesert S, Bruyère O, Berenbaum F, Brandi ML, Branco J, Devogelaer JP, Herrero-Beaumont G, Kanis J, Maggi S, Maheu E, Richette P, Rizzoli R, Cooper C.

Osteoarthritis Cartilage. 2015 Dec;23(12):2086-93. doi: 10.1016/j.joca.2015.07.001. Review.

8.

Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty.

Arden N, Richette P, Cooper C, Bruyère O, Abadie E, Branco J, Brandi ML, Berenbaum F, Clerc C, Dennison E, Devogelaer JP, Hochberg M, D'Hooghe P, Herrero-Beaumont G, Kanis JA, Laslop A, Leblanc V, Maggi S, Mautone G, Pelletier JP, Petit-Dop F, Reiter-Niesert S, Rizzoli R, Rovati L, Tajana Messi E, Tsouderos Y, Martel-Pelletier J, Reginster JY.

Drugs Aging. 2015 Jul;32(7):525-35. doi: 10.1007/s40266-015-0276-7. Review.

9.

Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis.

Reginster JY, Cooper C, Hochberg M, Pelletier JP, Rizzoli R, Kanis J, Abadie E, Maheu E, Brandi ML, Devogelaer JP, Branco J, Herrero-Beaumont G, D'Hooghe P, Bruyère O.

Curr Med Res Opin. 2015 May;31(5):1041-5. doi: 10.1185/03007995.2015.1027183.

PMID:
25753599
10.

Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis.

Bruyère O, Cooper C, Arden N, Branco J, Brandi ML, Herrero-Beaumont G, Berenbaum F, Dennison E, Devogelaer JP, Hochberg M, Kanis J, Laslop A, McAlindon T, Reiter S, Richette P, Rizzoli R, Reginster JY.

Drugs Aging. 2015 Mar;32(3):179-87. doi: 10.1007/s40266-015-0243-3.

11.

Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials.

Karsdal MA, Byrjalsen I, Alexandersen P, Bihlet A, Andersen JR, Riis BJ, Bay-Jensen AC, Christiansen C; CSMC021C2301/2 investigators..

Osteoarthritis Cartilage. 2015 Apr;23(4):532-43. doi: 10.1016/j.joca.2014.12.019.

12.

Goal-directed treatment of osteoporosis in Europe.

Kanis JA, McCloskey E, Branco J, Brandi ML, Dennison E, Devogelaer JP, Ferrari S, Kaufman JM, Papapoulos S, Reginster JY, Rizzoli R.

Osteoporos Int. 2014 Nov;25(11):2533-43. doi: 10.1007/s00198-014-2787-1.

PMID:
25199574
13.

Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid.

Devogelaer JP, Geusens P, Daci E, Gielen E, Denhaerynck K, Macdonald K, Hermans C, Vancayzeele S, Abraham I, Boonen S.

Calcif Tissue Int. 2014 Mar;94(3):311-8. doi: 10.1007/s00223-013-9812-9.

PMID:
24271562
14.

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial.

Bishop N, Adami S, Ahmed SF, Antón J, Arundel P, Burren CP, Devogelaer JP, Hangartner T, Hosszú E, Lane JM, Lorenc R, Mäkitie O, Munns CF, Paredes A, Pavlov H, Plotkin H, Raggio CL, Reyes ML, Schoenau E, Semler O, Sillence DO, Steiner RD.

Lancet. 2013 Oct 26;382(9902):1424-32. doi: 10.1016/S0140-6736(13)61091-0.

PMID:
23927913
15.

Health technology assessment in osteoporosis.

Hiligsmann M, Kanis JA, Compston J, Cooper C, Flamion B, Bergmann P, Body JJ, Boonen S, Bruyere O, Devogelaer JP, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY.

Calcif Tissue Int. 2013 Jul;93(1):1-14. doi: 10.1007/s00223-013-9724-8. Review.

16.

Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.

Devogelaer JP, Sambrook P, Reid DM, Goemaere S, Ish-Shalom S, Collette J, Su G, Bucci-Rechtweg C, Papanastasiou P, Reginster JY.

Rheumatology (Oxford). 2013 Jun;52(6):1058-69. doi: 10.1093/rheumatology/kes410.

17.

Treatment of osteoporosis in men.

Kaufman JM, Reginster JY, Boonen S, Brandi ML, Cooper C, Dere W, Devogelaer JP, Diez-Perez A, Kanis JA, McCloskey E, Mitlak B, Orwoll E, Ringe JD, Weryha G, Rizzoli R.

Bone. 2013 Mar;53(1):134-44. doi: 10.1016/j.bone.2012.11.018. Review.

18.

Management of glucocorticoid-induced osteoporosis.

Rizzoli R, Adachi JD, Cooper C, Dere W, Devogelaer JP, Diez-Perez A, Kanis JA, Laslop A, Mitlak B, Papapoulos S, Ralston S, Reiter S, Werhya G, Reginster JY.

Calcif Tissue Int. 2012 Oct;91(4):225-43. doi: 10.1007/s00223-012-9630-5. Review.

PMID:
22878667
19.

Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications.

Body JJ, Bergmann P, Boonen S, Devogelaer JP, Gielen E, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY.

Osteoporos Int. 2012 Feb;23 Suppl 1:S1-23. doi: 10.1007/s00198-011-1891-8.

20.

Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.

Reginster JY, Kaufman JM, Goemaere S, Devogelaer JP, Benhamou CL, Felsenberg D, Diaz-Curiel M, Brandi ML, Badurski J, Wark J, Balogh A, Bruyère O, Roux C.

Osteoporos Int. 2012 Mar;23(3):1115-22. doi: 10.1007/s00198-011-1847-z.

Items per page

Supplemental Content

Loading ...
Support Center